Prime Medicine Inc (PRME)

$5.33 -0.05 (-0.93%)
Market Cap 724.01M
Revenue (ttm) 2.98M
Net Income (ttm) -195.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,573.15%
Debt to Equity Ratio 0.00
Volume 1,814,700
Avg Vol 3,605,592
Day's Range N/A - N/A
Shares Out 134.57M
Stochastic %K 23%
Beta 2.65
Analysts Strong Sell
Price Target $6.78

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and peg...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 465 0013
Address:
60 First Street, Cambridge, United States
FredGS
FredGS Oct. 25 at 1:58 PM
$PRME Whenever I'm having a bad day, I listen to a $PRME conference call, or open my Think or Swim app and look at my shares. I think of the potential of this company and where we could be in 5 years!
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Oct. 24 at 9:14 PM
$PRME In my novice opinion the chart looks great. I hope we can get a positive update/partnership/approval soon
0 · Reply
Wax_Bean_futures
Wax_Bean_futures Oct. 24 at 6:46 PM
$PRME The Fuck?
1 · Reply
PorkchopSquats
PorkchopSquats Oct. 24 at 3:35 PM
$PRME Even lower volume, the lowest volume opening 2h bar we have seen since September 12. Look at the chart, what happened right after that?
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 3:06 PM
Enter: $PRME NOV 21 2025 $6 CALLS Buy in Price: $0.46 - $0.50 Take Profit: $0.63 Stop Bleeding: $0.40 ROI Potential: 37% https://moneygroup.us/
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Oct. 24 at 2:55 PM
$PRME Daily Deion
0 · Reply
FredGS
FredGS Oct. 24 at 12:48 PM
$PRME I like the new CEO Allan Reine. After watching this weeks panel discussion he would be the CEO I'd pick for running $PRME . He knows his stuff and has a quiet confidence that prime editing will be the winning gene editing technology over the next 5-10 years.
0 · Reply
sergiustrading
sergiustrading Oct. 24 at 8:48 AM
$PRME
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Oct. 24 at 3:04 AM
$PRME not big movement again. tomorrow could be another good day #mcnultyindicator
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Oct. 23 at 9:44 PM
$PRME Maybe?
0 · Reply
Latest News on PRME
Prime Medicine to Participate in Upcoming Investor Conferences

Oct 7, 2025, 8:00 AM EDT - 18 days ago

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 5:38 PM EDT - 6 weeks ago

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 8:07 PM EDT - 7 weeks ago

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Aug 1, 2025, 4:01 PM EDT - 3 months ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 9:33 PM EDT - 3 months ago

Prime Medicine Announces Pricing of Public Offering

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 30, 2025, 4:01 PM EDT - 3 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 8:10 AM EDT - 3 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 16, 2025, 7:00 AM EDT - 3 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Jul 7, 2025, 4:45 PM EDT - 3 months ago

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:31 AM EDT - 5 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 19, 2025, 8:30 AM EDT - 5 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

May 8, 2025, 8:00 AM EDT - 6 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Mar 18, 2025, 7:00 AM EDT - 7 months ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 28, 2025, 8:00 AM EST - 8 months ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 8 months ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Jan 30, 2025, 12:26 PM EST - 9 months ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

Nov 26, 2024, 5:10 AM EST - 11 months ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 12:17 PM EDT - 1 year ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

Sep 30, 2024, 8:38 AM EDT - 1 year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Prime Medicine Unveils Strategically Focused Pipeline

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 13, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Alphabet Bought Up Two Slumping Stocks

May 12, 2024, 3:00 AM EDT - 1 year ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 10, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

May 8, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 1, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 20, 2024, 4:01 PM EST - 1 year ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Upsized Public Offering

Feb 14, 2024, 11:50 PM EST - 1 year ago

Prime Medicine Announces Pricing of Upsized Public Offering

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 28, 2024, 8:11 AM EST - 1 year ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 25, 2024, 8:00 AM EST - 1 year ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Jan 5, 2024, 8:00 AM EST - 1 year ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 1 year ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

Dec 1, 2023, 2:45 PM EST - 2 years ago

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

CRSP

Prime Medicine to Present at Upcoming Investor Conferences

Nov 8, 2023, 8:00 AM EST - 2 years ago

Prime Medicine to Present at Upcoming Investor Conferences

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 3, 2023, 4:01 PM EDT - 2 years ago

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Oct 27, 2023, 6:00 AM EDT - 2 years ago

Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences

Prime Medicine: Not Yet Primed For Retail Investment

Sep 27, 2023, 8:49 AM EDT - 2 years ago

Prime Medicine: Not Yet Primed For Retail Investment

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 7, 2023, 4:01 PM EDT - 2 years ago

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

Jun 22, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

Prime Medicine to Present at Investor Conferences in June

May 31, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine to Present at Investor Conferences in June

Prime Medicine to Present at Virtual Investor Conferences in May

May 17, 2023, 4:05 PM EDT - 2 years ago

Prime Medicine to Present at Virtual Investor Conferences in May

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

May 17, 2023, 6:00 AM EDT - 2 years ago

Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting

FredGS
FredGS Oct. 25 at 1:58 PM
$PRME Whenever I'm having a bad day, I listen to a $PRME conference call, or open my Think or Swim app and look at my shares. I think of the potential of this company and where we could be in 5 years!
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Oct. 24 at 9:14 PM
$PRME In my novice opinion the chart looks great. I hope we can get a positive update/partnership/approval soon
0 · Reply
Wax_Bean_futures
Wax_Bean_futures Oct. 24 at 6:46 PM
$PRME The Fuck?
1 · Reply
PorkchopSquats
PorkchopSquats Oct. 24 at 3:35 PM
$PRME Even lower volume, the lowest volume opening 2h bar we have seen since September 12. Look at the chart, what happened right after that?
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 24 at 3:06 PM
Enter: $PRME NOV 21 2025 $6 CALLS Buy in Price: $0.46 - $0.50 Take Profit: $0.63 Stop Bleeding: $0.40 ROI Potential: 37% https://moneygroup.us/
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Oct. 24 at 2:55 PM
$PRME Daily Deion
0 · Reply
FredGS
FredGS Oct. 24 at 12:48 PM
$PRME I like the new CEO Allan Reine. After watching this weeks panel discussion he would be the CEO I'd pick for running $PRME . He knows his stuff and has a quiet confidence that prime editing will be the winning gene editing technology over the next 5-10 years.
0 · Reply
sergiustrading
sergiustrading Oct. 24 at 8:48 AM
$PRME
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Oct. 24 at 3:04 AM
$PRME not big movement again. tomorrow could be another good day #mcnultyindicator
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Oct. 23 at 9:44 PM
$PRME Maybe?
0 · Reply
RocroBio
RocroBio Oct. 23 at 9:27 PM
$PRME
0 · Reply
cannontrades
cannontrades Oct. 23 at 8:10 PM
$PRME $NTLA Don't believe me? Just watch.
1 · Reply
EBITDAD
EBITDAD Oct. 23 at 7:10 PM
$PRME @Mcnulty_jimmy
1 · Reply
PorkchopSquats
PorkchopSquats Oct. 23 at 5:54 PM
$PRME Yesterday we eclipsed 1M volume in the first 30 minutes and got the second highest volume all month. Today we are at not even 1.6M after almost 4.5 hours, on pace for the lowest volume day this month. This must have been shorted into the dirt yesterday to try and break structure.
0 · Reply
EBITDAD
EBITDAD Oct. 23 at 2:48 PM
$PRME WELL WELL WELL
0 · Reply
StockMarketGuru
StockMarketGuru Oct. 23 at 2:47 PM
$PRME
0 · Reply
cannontrades
cannontrades Oct. 23 at 2:41 PM
$PRME SUPER bullish on this. Great retest of 4.90-5.20 area in a textbook bull flag pattern. This will see 8's - high conviction here. Chart is looking better than $NTLA actually. I trimmed some over there and moved more to PRME as I think more % gain will be here in the next months
0 · Reply
WM_trader
WM_trader Oct. 23 at 2:24 PM
$PRME Let's go!!! Bought extra to lower my average.
1 · Reply
EBITDAD
EBITDAD Oct. 23 at 2:15 PM
$PRME
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 23 at 2:11 PM
Enter: $PRME NOV 21 2025 $6 CALLS Buy in Price: $0.45 - $0.47 Take Profit: $1.09 Stop Bleeding: $0.40 ROI Potential: 143% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
Mcnulty_jimmy
Mcnulty_jimmy Oct. 23 at 2:11 PM
$PRME Daily Deion
0 · Reply
EBITDAD
EBITDAD Oct. 23 at 1:47 PM
$PRME perhaps we needed a haircut
0 · Reply